Related Experiment Videos
Zolmitriptan provides consistent migraine relief when used in the long-term.
M Tuchman1, L Edvinsson, G Geraud
1Palm Beach Neurological Group, Palm Beach Gardens, Florida 33410, USA.
Current Medical Research and Opinion
|January 20, 2000
Summary
Zolmitriptan effectively treats migraine attacks, offering consistent headache relief for patients. This medication proved reliable regardless of migraine type, patient demographics, or menstrual cycle association.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine is a debilitating chronic neurological disease impacting quality of life.
- Effective and consistent treatments are crucial for managing the migraine burden.
Purpose of the Study:
- To evaluate the efficacy and consistency of zolmitriptan (2.5 mg and 5 mg) in treating multiple migraine attacks.
- To assess treatment response across different migraine characteristics and patient demographics.
Main Methods:
- An open-label study phase allowed patients to self-manage migraine attacks with zolmitriptan.
- Headache response and pain-free rates were assessed within two hours post-dosing.
- Response consistency was analyzed in patients treating at least 20 attacks.
Main Results:
- Two-hour headache response rates for 2.5 mg and 5 mg zolmitriptan were 85% and 79%, respectively.
- Pain-free response rates were 69% and 59% for the respective doses.
- Responses were consistent within individual patients and unaffected by aura or menses association.
Conclusions:
- Zolmitriptan (2.5 mg and 5 mg) demonstrates consistent effectiveness for multiple migraine attacks in individual patients.
- Treatment efficacy is independent of patient gender, age, aura presence, or menstrual association.
- The study supports zolmitriptan as a reliable option for sustained migraine management.